|
Public Meeting on Essential Uses of Ozone Depleting Substances
August 2, 2007, Rockville, MD
The Food and Drug Administration (FDA) is announcing a public meeting to solicit comments on a proposed rule that would amend FDA's regulation on the use of ozone-depleting substances in self-pressurized containers to remove essential-use designations for certain oral pressurized metered-dose inhalers (MDIs). In the Federal Register of June 11, 2007 (72 FR 32030), the agency proposed to remove the essential use designation for MDIs containing flunisolide, triamcinolone, metaproterenol, pirbuterol, albuterol and ipratropium in combination, cromolyn, and nedocromil. Information from the public meeting, which is required by agency regulations, will be considered in finalizing the rulemaking.
- Meeting Notice (Federal Register) [HTML] [PDF]
- Proposed Rule [HTML] [PDF]
- Agenda
- Meeting Presentations
Back
to Top
Back to Meetings
PDF requires the free Adobe Acrobat Reader
Date created: July 31, 2007, updated August 3, 2007 |
|